Drug intelligence / Profile preview

depigmented modified mite allergen extract + Dermatophagoides pteronyssinus + Blomia tropicalis

Development stage: Unknown
Lead developer: Leti Pharma
Modality: Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

DP/MG/14-2 is a subcutaneous allergen immunotherapy (SCIT) product developed by Laboratorios LETI S.L.U. It is a biologic allergoid consisting of a depigmented, glutaraldehyde-polymerised mite allergen extract mixture. The product combines extracts from two house dust mite species, *Dermatophagoides pteronyssinus* and *Blomia tropicalis*. It is designed to treat allergic rhinitis, rhinoconjunctivitis, and allergic asthma by modulating the patient's IgE-mediated immune response and inducing allergen tolerance. The drug has been evaluated in Phase IIb clinical trials, particularly for patients co-sensitised to both mite species in regions like the Canary Islands where such co-sensitisation is common.

Other names: depigmented modified mite allergen extract mixtureDermatophagoides pteronyssinus + Blomia tropicalis allergoid

Targets

sIgG4 (Allergen-specific immunoglobulin G4)BCR (Immunoglobulin G B Cell Receptor)TCR (T cell antigen receptor complex)A. annua-specific IgE (Artemisia annua-specific immunoglobulin E)

Beyond the preview

Go deeper on depigmented modified mite allergen extract + Dermatophagoides pteronyssinus + Blomia tropicalis.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on depigmented modified mite allergen extract + Dermatophagoides pteronyssinus + Blomia tropicalis.

Explore the full profile